表紙
市場調査レポート

胃癌:パイプライン分析

Gastric Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232773
出版日 ページ情報 英文 962 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
胃癌:パイプライン分析 Gastric Cancer - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 962 Pages
概要

胃癌は、胃の内膜に発生する悪性腫瘍で、その兆候と症状には、倦怠感、腹痛、嘔吐、体重の減少、食後の膨満感、胸やけ、消化不良などがあります。胃癌を罹患する原因としては、喫煙、2悪性貧血、胃のポリープ、ピロリ菌への感染、胃癌を発症しやすい家系などが挙げられます。

当レポートでは、胃癌治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

胃癌の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

胃癌:企業で開発中の治療薬

胃癌:大学/機関で研究中の治療薬

胃癌:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

胃癌:企業で開発中の製品

胃癌:大学/機関で研究中の製品

胃癌の治療薬開発に従事している企業

胃癌:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

胃癌:最近のパイプライン動向

胃癌:休止中のプロジェクト

胃癌:開発が中止された製品

胃癌:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7815IDB

Summary

Global Markets Direct's, 'Gastric Cancer - Pipeline Review, H1 2016', provides an overview of the Gastric Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastric Cancer
  • The report reviews pipeline therapeutics for Gastric Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Gastric Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Gastric Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Gastric Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Gastric Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Gastric Cancer Overview
  • Therapeutics Development
    • Gastric Cancer - Therapeutics under Development by Companies
    • Gastric Cancer - Therapeutics under Investigation by Universities/Institutes
    • Gastric Cancer - Pipeline Products Glance
    • Gastric Cancer - Products under Development by Companies
    • Gastric Cancer - Products under Investigation by Universities/Institutes
    • Gastric Cancer - Companies Involved in Therapeutics Development
    • Gastric Cancer - Therapeutics Assessment
  • Drug Profiles
    • Gastric Cancer - Recent Pipeline Updates
    • Gastric Cancer - Dormant Projects
    • Gastric Cancer - Discontinued Products
    • Gastric Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Gastric Cancer, H1 2016
  • Number of Products under Development for Gastric Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Gastric Cancer - Pipeline by AB Science SA, H1 2016
  • Gastric Cancer - Pipeline by AbbVie Inc., H1 2016
  • Gastric Cancer - Pipeline by AbGenomics International, Inc., H1 2016
  • Gastric Cancer - Pipeline by ADC Therapeutics Sarl, H1 2016
  • Gastric Cancer - Pipeline by Advaxis, Inc., H1 2016
  • Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Gastric Cancer - Pipeline by Agenus, Inc., H1 2016
  • Gastric Cancer - Pipeline by Ambrx, Inc., H1 2016
  • Gastric Cancer - Pipeline by Amgen Inc., H1 2016
  • Gastric Cancer - Pipeline by arGEN-X BV, H1 2016
  • Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016
  • Gastric Cancer - Pipeline by Astellas Pharma Inc., H1 2016
  • Gastric Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Gastric Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Athenex, Inc., H1 2016
  • Gastric Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2016
  • Gastric Cancer - Pipeline by Bayer AG, H1 2016
  • Gastric Cancer - Pipeline by BeiGene, Ltd., H1 2016
  • Gastric Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016
  • Gastric Cancer - Pipeline by Bionovis SA, H1 2016
  • Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Gastric Cancer - Pipeline by Boston Biomedical, Inc., H1 2016
  • Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Gastric Cancer - Pipeline by Celgene Corporation, H1 2016
  • Gastric Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016
  • Gastric Cancer - Pipeline by Celltrion, Inc., H1 2016
  • Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2016
  • Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016
  • Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Gastric Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by Compliment Corporation, H1 2016
  • Gastric Cancer - Pipeline by Curaxys, S.L., H1 2016
  • Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016
  • Gastric Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Gastric Cancer - Pipeline by Eddingpharm, H1 2016
  • Gastric Cancer - Pipeline by EirGenix Inc., H1 2016
  • Gastric Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Gastric Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016
  • Gastric Cancer - Pipeline by Exelixis, Inc., H1 2016
  • Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Frost Biologic, Inc., H1 2016
  • Gastric Cancer - Pipeline by Galena Biopharma, Inc., H1 2016
  • Gastric Cancer - Pipeline by Genelux Corporation, H1 2016
  • Gastric Cancer - Pipeline by Genentech, Inc., H1 2016
  • Gastric Cancer - Pipeline by Gilead Sciences, Inc., H1 2016
  • Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Gastric Cancer - Pipeline by GlycoNex Inc., H1 2016
  • Gastric Cancer - Pipeline by Glycotope GmbH, H1 2016
  • Gastric Cancer - Pipeline by Green Cross Corporation, H1 2016
  • Gastric Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Gastric Cancer - Pipeline by Hetero Drugs Limited, H1 2016
  • Gastric Cancer - Pipeline by Horizon Pharma Plc, H1 2016
  • Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Gastric Cancer - Pipeline by Ignyta, Inc., H1 2016
  • Gastric Cancer - Pipeline by Immunomedics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Incyte Corporation, H1 2016
  • Gastric Cancer - Pipeline by Innovent Biologics, Inc., H1 2016
  • Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H1 2016
  • Gastric Cancer - Pipeline by ISU ABXIS Co.,Ltd., H1 2016
  • Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by Johnson & Johnson, H1 2016
  • Gastric Cancer - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016
  • Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
  • Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by LegoChem Biosciences, Inc, H1 2016
  • Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Gastric Cancer - Pipeline by MacroGenics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by MedImmune, LLC, H1 2016
  • Gastric Cancer - Pipeline by Medivation, Inc., H1 2016
  • Gastric Cancer - Pipeline by Merck & Co., Inc., H1 2016
  • Gastric Cancer - Pipeline by Merck KGaA, H1 2016
  • Gastric Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
  • Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Merus B.V., H1 2016
  • Gastric Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H1 2016
  • Gastric Cancer - Pipeline by MolMed S.p.A., H1 2016
  • Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by Novartis AG, H1 2016
  • Gastric Cancer - Pipeline by OBI Pharma, Inc., H1 2016
  • Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016
  • Gastric Cancer - Pipeline by Oncobiologics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Oncolys BioPharma Inc., H1 2016
  • Gastric Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016
  • Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H1 2016
  • Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by Panacea Biotec Limited, H1 2016
  • Gastric Cancer - Pipeline by Patrys Limited, H1 2016
  • Gastric Cancer - Pipeline by Pfizer Inc., H1 2016
  • Gastric Cancer - Pipeline by Pharma Mar, S.A., H1 2016
  • Gastric Cancer - Pipeline by Pharmacyclics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016
  • Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016
  • Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H1 2016
  • Gastric Cancer - Pipeline by Sanofi, H1 2016
  • Gastric Cancer - Pipeline by Sareum Holdings Plc, H1 2016
  • Gastric Cancer - Pipeline by Sequella, Inc., H1 2016
  • Gastric Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
  • Gastric Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2016
  • Gastric Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • Gastric Cancer - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016
  • Gastric Cancer - Pipeline by Supratek Pharma Inc., H1 2016
  • Gastric Cancer - Pipeline by Synovo GmbH, H1 2016
  • Gastric Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016
  • Gastric Cancer - Pipeline by Synthon Holdings BV, H1 2016
  • Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
  • Gastric Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Gastric Cancer - Pipeline by Takis S.r.l., H1 2016
  • Gastric Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016
  • Gastric Cancer - Pipeline by TG Therapeutics, Inc., H1 2016
  • Gastric Cancer - Pipeline by Transgene SA, H1 2016
  • Gastric Cancer - Pipeline by Vaxon Biotech, H1 2016
  • Gastric Cancer - Pipeline by ViiV Healthcare Limited, H1 2016
  • Gastric Cancer - Pipeline by Zymeworks Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Gastric Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Gastric Cancer - Dormant Projects, H1 2016
  • Gastric Cancer - Dormant Projects (Contd..1), H1 2016
  • Gastric Cancer - Dormant Projects (Contd..2), H1 2016
  • Gastric Cancer - Dormant Projects (Contd..3), H1 2016
  • Gastric Cancer - Dormant Projects (Contd..4), H1 2016
  • Gastric Cancer - Dormant Projects (Contd..5), H1 2016
  • Gastric Cancer - Dormant Projects (Contd..6), H1 2016
  • Gastric Cancer - Dormant Projects (Contd..7), H1 2016
  • Gastric Cancer - Dormant Projects (Contd..8), H1 2016
  • Gastric Cancer - Dormant Projects (Contd..9), H1 2016
  • Gastric Cancer - Dormant Projects (Contd..10), H1 2016
  • Gastric Cancer - Discontinued Products, H1 2016
  • Gastric Cancer - Discontinued Products (Contd..1), H1 2016
  • Gastric Cancer - Discontinued Products (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for Gastric Cancer, H1 2016
  • Number of Products under Development for Gastric Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top